镜像单域抗体用于一种新型非免疫原药物基架
Keisuke Aoki1,2, Asako Manabe3, Hiroyuki Kimura4
1Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.
Bioconjugate chemistry
|October 26, 2023
概括
与标准VHH相比,镜像VHH蛋白 (d-VHHs) 的免疫性降低,为具有较低副作用的新型蛋白质疗法提供了有希望的途径. 这些d-VHHs对降解的敏感性较小,提高了它们的治疗潜力.
科学领域:
- 生物技术是生物技术.
- 免疫学 免疫学 免疫学
- 蛋白质工程是指蛋白质工程.
背景情况:
- 蛋白质疗法可以引起免疫反应,从而通过产生抗体减少疗效和副作用.
- 镜像VHHs (d-VHHs) 是工程化蛋白质,由于抗原呈现细胞中对蛋白质分解的抵抗,其免疫性可能会降低.
研究的目的:
- 研究d-VHHs的制备方案和生物特性,重点关注立体选择性结合和免疫性.
- 评估d-VHHs作为具有降低免疫原性特征的新型蛋白质治疗药物的潜力.
主要方法:
- 开发了一种三步原生化学结合 (NCL) 工艺,用于合成模型VHHs及其镜像对应物.
- 评估了原生 (l-VHH) 和镜像 (d-VHH) 蛋白质的目标结合特异性.
- 在小鼠中使用放射性标记的VHH和d-VHH进行生物分布研究.
- 通过测量l-VHHs和d-VHHs的注射后抗药抗体 (ADA) 生产的免疫性比较.
主要成果:
- 合成的l-VHHs表现出对标蛋白的特定结合,而d-VHHs没有结合本地标,证实了立体选择性.
- l-VHHs和d-VHHs的生物分布概况相似,由于体积小,脏积累迅速.
- 与原生VHH相比,d-VHHs诱导的ADA生成水平显著较低,不论其序列或给药途径.
结论:
- 已建立的合成协议有助于制备d-VHHs.
- d-VHHs表现出降低的免疫性,为开发更安全的蛋白质疗法提供了可行的策略.
- d-VHH 支架可以适应设计针对各种蛋白质的新疗法.
相关概念视频
01:10Antibody Structure
60.2K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.2K
01:31Hybridoma Technology
14.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.8K